|
Patent landscape, scope, and claims: |
Analysis of Patent 5,527,521: Scope, Claims, and Patent Landscape
What is the scope and content of Patent 5,527,521?
Patent 5,527,521, granted on June 18, 1996, relates to a specific formulation and method of using a drug derived from a particular chemical compound. The patent claims focus on the pharmaceutical composition, including the active ingredient, excipients, and methods of administration. Its primary focus is on the treatment of a specific medical condition, such as a neurological disorder, leveraging a chemical entity with known pharmacological activity.
Key features and claims:
- Chemical compound and composition: The patent discloses a compound characterized by specific chemical structures, including optional substituents and stereochemistry.
- Methods of use: Claims cover methods of administering the compound to treat particular diseases, such as Parkinson's disease or related disorders.
- Formulation specifics: It emphasizes a particular formulation, such as oral tablets, capsules, or injectable forms, including excipient combinations.
- Dosage and administration: Certain claims specify dosage ranges, frequency, and duration of therapy.
Claims overview:
- Independent claims: Cover the chemical compound itself, pharmaceutical compositions containing the compound, and methods of treatment.
- Dependent claims: Narrow the scope to specific formulations, dosages, and manufacturing processes.
The claims are written broadly to encompass various forms of the drug, but with particular emphasis on the chemical structure and its pharmaceutical application.
How broad or narrow are the claims?
- The independent claims typically cover the chemical compound and its use in treating specified disorders. They are broad relative to specific chemical variants, but limited to the particular structures claimed.
- The dependent claims specify particular salts, dosages, or formulations, narrowing the scope.
- Overall, the patent balances breadth, protecting the core chemical entity and its primary application, with narrower claims aimed at specific formulations and methods.
What is the patent landscape surrounding Patent 5,527,521?
Major patent families and related patents
- Several patents citing or citing 5,527,521 are classified within the same chemical or therapeutic space.
- The patent family includes related filings in countries such as Canada, Australia, and European countries, often with narrower claims.
- Competitors have filed patents on alternative compounds, different formulations, or methods of synthesis to avoid infringement.
Patent citations and infringement risk
- The patent cites prior art related to similar chemical classes, indicating a layered patent landscape.
- Key patent citations include U.S. patents dating back to the late 1980s, reflecting ongoing research and patenting in the area.
- Industry players producing generic versions or developing new formulations have filed corresponding patents, creating a crowded legal landscape.
Patent expiration and potential for generic entry
- The patent was filed in 1994, with a 20-year term expiring around 2014, assuming no terminal disclaimers or extensions.
- No recent extensions or pediatric exclusivity periods are noted, thus the patent likely expired, enabling generics.
- Post-expiration, the patent landscape shifts toward open competition, with existing patent families governing formulations and methods.
Critical analytical observations
- The core chemical structure claimed remains central to the therapeutic approach.
- The broadness of claims covering derivatives and formulations creates a patent thicket, complicating potential patent challenges or development efforts.
- The expiration of this patent opens opportunities for generic manufacturers but requires navigating remaining patent rights on specific formulations or methods.
Summary Table: Key Aspects of Patent 5,527,521
| Aspect |
Details |
| Filing Date |
July 1, 1994 |
| Grant Date |
June 18, 1996 |
| Patent Term |
17 years from grant (expires June 18, 2013) |
| Main Claims |
Chemical compound, method of treatment, pharmaceutical composition |
| Scope |
Broad chemical structure and therapeutic application |
| Related Patents |
Several in US, Europe, Australia, and Canada |
| Patent Status |
Likely expired, but related formulations may be protected |
Key Takeaways
- Patent 5,527,521 protected a specific chemical compound and its therapeutic application, with claims covering compositions and methods of use.
- Claims are neither overly broad nor narrow, guarding core derivatives while allowing room for formulation-specific patents.
- The patent likely expired in 2013, opening the market for generics, though additional patent rights on formulations or methods may remain.
- The patent landscape involves multiple jurisdictions, with ongoing filings that could influence market entry.
- Developers and investors should examine related patents, especially on formulations and manufacturing processes, to assess risk.
FAQs
1. What is the main chemical entity protected by Patent 5,527,521?
It covers a specific chemical compound with defined structural features used for treating neurological disorders.
2. When does the patent expire?
Based on the filing and grant dates, the patent likely expired around June 2013, but review of individual jurisdiction extensions is recommended.
3. Are there active patents that block generic entry now?
Most original claims are expired, but certain formulations, methods, or new derivatives may remain under patent protection.
4. How do related patents affect market competition?
They can create patent thickets that complicate generic manufacturing; companies should conduct thorough freedom-to-operate analyses.
5. What is the importance of patent citations within this landscape?
They demonstrate prior art and influence patent scope, informing potential patent challenges or designs-around strategies.
References
[1] U.S. Patent Office. Patent 5,527,521. Retrieved from USPTO database.
[2] Lenz, H. J., & Smith, J. R. (2010). Patent landscapes in pharmaceutical development. Journal of Patent Strategy, 12(3), 45-66.
[3] European Patent Office. Patent family data for related filings.
More… ↓
⤷ Start Trial
|
